Anna Dorothea Wagner

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


92 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2001 | 1998 | 1996 |
2024
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
2023
 
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
Margalit O., Harmsen W.S., Shacham-Shmueli E., Voss M.M., Boursi B., Wagner A.D., Cohen R., Olswold C.L., Saltz L.B., Goldstein D.A. et al., 2023/11. European journal of cancer, 194 p. 113339. Peer-reviewed.
[DOI][Pmid][serval:BIB_F88116DF20BF]
 
Gender differences in tumor characteristics, treatment and survival of colorectal cancer: A population-based study.
van Erning F.N., Greidanus NEM, Verhoeven RHA, Buijsen J., de Wilt H.W., Wagner D., Creemers G.J., 2023/10. Cancer epidemiology, 86 p. 102441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_639F911C9D12]
Esophageal cancer T-staging on MRI: A preliminary study using cine and static MR sequences.
Haefliger L., Jreige M., Du Pasquier C., Ledoux J.B., Wagner D., Mantziari S., Shäfer M., Vietti Violi N., Dromain C., 2023/09. European journal of radiology, 166 p. 111001. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3DB02D052A3]
Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
Kalff M.C., Dijksterhuis WPM, Wagner A.D., Oertelt-Prigione S., Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz S.S., van Berge Henegouwen M.I., 2023/07. European journal of cancer, 187 pp. 114-123. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5B8DD083A7EC]
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L., Resche-Rigon M., Dromain C., Lamarca A., La Salvia A., de Baker L., Fehrenbach U., Pusceddu S., Colao A., Borbath I. et al., 2023/06. Journal of neuroendocrinology, 35 (6) pp. e13311. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A27AF92DDE2]
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese T.E., van Laarhoven HWM, Schoppman S.F., Deseyne PRAJ, van Cutsem E., Haustermans K., Nafteux P., Thomas M., Obermannova R., Mortensen H.R. et al., 2023/05. European journal of cancer, 185 pp. 28-39. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0D7216745F58]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Margalit O., Harmsen W.S., Shacham-Shmueli E., Voss M.M., Boursi B., Wagner A.D., Cohen R., Olswold C.L., Saltz L.B., Goldstein D.A. et al., 2023/01. European journal of cancer, 178 pp. 162-170. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A89637C6063]
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
Briki M., André P., Thoma Y., Widmer N., Wagner A.D., Decosterd L.A., Buclin T., Guidi M., Carrara S., 2023. Pharmaceutics, 15 (4) p. 1283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A82A8DDE8796]
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer.
Kroese T.E., van Rossum PSN, Nilsson M., Lordick F., Smyth E.C., Rosati R., Nafteux P., D'Ugo D., Chaudry M.A., Polkowkski W. et al., 2023/01. European journal of surgical oncology, 49 (1) pp. 21-28. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F9C8EA647E0C]
2022
 
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.
Panje C., Hayoz S., Eisterer W., Hess V., Thuss-Patience P., Schacher S., Dürr D., Wagner A.D., Girschikofsky M., Eboulet E. et al., 2022/12. European journal of cancer, 177 pp. 186-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F9CAE3DCD0B4]
 
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M., Högner A., Wagner A.D., Obermannova R., Alsina M., Thuss-Patience P., van Laarhoven H., Smyth E., 2022/11. European journal of cancer, 176 pp. 13-29. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6378883AE7D4]
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature.
McNamara M.G., Bridgewater J., Goyal L., Jacobs T., Wagner A.D., Goldstein D., Shroff R., Moehler M., Lowery M., Bekaii-Saab T. et al., 2022/10/26. BMJ open, 12 (10) pp. e064954. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F26107797F0E]
 
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group.
Sclafani F., Fontana E., Wyrwicz L., Wagner A.D., Valle J.W., Smyth E., Peeters M., Obermannova R., Neuzillet C., Lutz M.P. et al., 2022/09. Clinical colorectal cancer, 21 (3) pp. 188-197. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_700C97DDB27C]
 
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
Quaas A., Biesma H.D., Wagner A.D., Verheij M., van Berge Henegouwen M.I., Schoemig-Markiefka B., Pamuk A., Zander T., Siemanowski J., Sikorska K. et al., 2022/09. European journal of cancer, 173 pp. 95-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F864F08541F]
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P., Cardoso E., Bandiera C., Stravodimou A., Zurcher J.P., Chtioui H., Locatelli I., Decosterd L.A., Darnaud L., Blanchet B. et al., 2022/06/21. Pharmaceutics, 14 (7) p. 1317. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E7FBC59504B2]
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.
Koessler T., Alsina M., Arnold D., Ben-Aharon I., Collienne M., Lutz M.P., Neuzillet C., Obermannova R., Peeters M., Sclafani F. et al., 2022/04. ESMO open, 7 (2) p. 100392. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_851DF44B5BE1]
 
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Kroese T.E., van Hillegersberg R., Schoppmann S., Deseyne PRAJ, Nafteux P., Obermannova R., Nordsmark M., Pfeiffer P., Hawkins M.A., Smyth E. et al., 2022/03. European journal of cancer, 164 pp. 18-29. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A66490D09189]
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences.
Zander T., Wagner A.D., 2022/02/21. Cancers, 14 (4) p. 1088. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B420C71B37F7]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
 
Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force.
Özdemir B.C., Oertelt-Prigione S., Adjei A.A., Borchmann S., Haanen J.B., Letsch A., Mir O., Quaas A., Verhoeven RHA, Wagner A.D., 2022/02. Annals of oncology, 33 (2) pp. 126-128. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_60480A3079B7]
 
Consideration of sex and gender aspects in oncology: rationale, curent status, and perspectives
Wagner Anna, Oezdemir Berna, 2022. Italian Journal of Sex- and Gender-specific Medicine, 8 (1) pp. 55-58. Peer-reviewed.
[serval:BIB_5B967CA1C315]
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Bandiera C., Pasquier J., Locatelli I., Niquille A., Wuerzner G., Dotta-Celio J., Hachfeld A., Wandeler G., Wagner A.D., Csajka C. et al., 2022. Patient preference and adherence, 16 pp. 2313-2320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813F43A545D0]
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit.
Kalff M.C., Wagner A.D., Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz S.S., van Berge Henegouwen M.I., Dutch Upper GI Cancer Audit group, 2022/01. Gastric cancer, 25 (1) pp. 22-32. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3C125C4BB6B6]
Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study.
Pijnappel E.N., Schuurman M., Wagner A.D., de Vos-Geelen J., van der Geest LGM, de Groot J.B., Koerkamp B.G., de Hingh IHJT, Homs MYV, Creemers G.J. et al., 2022. Frontiers in oncology, 12 p. 839779. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A44EFB021E8D]
2021
Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study.
Dijksterhuis WPM, Kalff M.C., Wagner A.D., Verhoeven RHA, Lemmens VEPP, van Oijen MGH, Gisbertz S.S., van Berge Henegouwen M.I., van Laarhoven HWM, 2021/11/02. Journal of the National Cancer Institute, 113 (11) pp. 1551-1560. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_949817C75DEC]
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.
Koessler T., Alsina M., Arnold D., Ben-Aharon I., Lutz M.P., Obermannova R., Peeters M., Sclafani F., Smyth E., Valle J.W. et al., 2021/09. British journal of cancer, 125 (7) pp. 911-919. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9EA83BC830BF]
 
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Wagner A.D., Grothey A., Andre T., Dixon J.G., Wolmark N., Haller D.G., Allegra C.J., de Gramont A., VanCutsem E., Alberts S.R. et al., 2021/04/06. Journal of the National Cancer Institute, 113 (4) pp. 400-407. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45389DDD78CB]
2020
 
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara M.G., Lopes A., Wasan H., Malka D., Goldstein D., Shannon J., Okusaka T., Knox J.J., Wagner A.D., André T. et al., 2020/11. Journal of hepatology, 73 (5) pp. 1109-1117. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0EE5ED2AA22A]
Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely
Özdemir Berna, Wagner Anna Dorothea, 2020/10/12. healthbook TIMES Oncology Hematology 5.
[URN][DOI][serval:BIB_1452A08F64C5]
Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy.
Wagner A.D., 2020/09. ESMO open, 5 (5) pp. e000770. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A7C30FCAAE3]
 
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position.
Levy A., Wagner A.D., Chargari C., Moehler M., Verheij M., Durand-Labrunie J., Kissel M., Chirat E., Burtin P., Ducreux M. et al., 2020/08. European journal of cancer, 135 pp. 103-112. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DAD4904FA6D1]
 
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Cardoso E., Guidi M., Khoudour N., Boudou-Rouquette P., Fabre E., Tlemsani C., Arrondeau J., Goldwasser F., Vidal M., Schneider M.P. et al., 2020/07. Clinical therapeutics, 42 (7) pp. 1302-1316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C945C7298567]
 
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R., Vernerey D., Bellera C., Meurisse A., Henriques J., Paoletti X., Rousseau B., Alberts S., Aparicio T., Boukovinas I. et al., 2020/05. European journal of cancer, 130 pp. 63-71. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D4332D75C365]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][Pmid][serval:BIB_7B31C4DA5F5B]
 
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A., De Dosso S., Meisel A., Wagner A.D., Borner M., 2020. Oncology research and treatment, 43 (5) pp. 237-244. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FF92BBB469D2]
Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
Wagner A.D., Lordick F., Grabsch H.I., Terashima M., Terada M., Yoshikawa T., Boku N., Kataoka K., Smyth E.C., Mauer M. et al., 2020/01. European journal of cancer, 124 pp. 67-76. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35163E169A37]
2019
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7C76EA90383]
 
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
Davidson M., Wagner A.D., Kouvelakis K., Nanji H., Starling N., Chau I., Watkins D., Rao S., Peckitt C., Cunningham D., 2019/11. European journal of cancer, 121 pp. 40-47. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD8C86867293]
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Bassani-Sternberg Michal, Digklia Antonia, Huber Florian, Wagner Dorothea, Sempoux Christine, Stevenson Brian J., Thierry Anne-Christine, Michaux Justine, Pak HuiSong, Racle Julien et al., 2019/08/08. Frontiers in Immunology, 10 p. 1832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0144F5D289B5]
Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer
Özdemir Berna C, Moehler Markus, Syn Nicholas LX, Tai Bee-Choo, Wagner Anna Dorothea, 2019/07/03. Cochrane Database of Systematic Reviews.
[URN][DOI][serval:BIB_EE24E14551F4]
 
Human epidermal growth factor receptor 2-positive digestive tumors.
Wagner A.D., Özdemir B.C., Rüschoff J., 2019/07. Current opinion in oncology, 31 (4) pp. 354-361. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_79ED6368F476]
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner A.D., Grabsch H.I., Mauer M., Marreaud S., Caballero C., Thuss-Patience P., Mueller L., Elme A., Moehler M.H., Martens U. et al., 2019/05/24. BMC cancer, 19 (1) p. 494. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D31BF0D4734]
 
The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
Lutz M.P., Zalcberg J.R., Ducreux M., Adenis A., Allum W., Aust D., Carneiro F., Grabsch H.I., Laurent-Puig P., Lordick F. et al., 2019/05. European journal of cancer, 112 pp. 1-8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5456782E7024]
 
Reply to L. Pala et al.
Wagner A.D., Özdemir B., Csajka C., 2019/02/10. Journal of clinical oncology, 37 (5) pp. 439-440. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3B355EA54937]
Inappropriate Grading of Adverse Events in Cancer Clinical Trials-Reply.
Cristina V., Mauer M., Wagner A.D., 2019/02/01. JAMA oncology, 5 (2) pp. 269-270. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D4F7397E30A8]
A Novel Approach to Better Characterize Medication Adherence in Oral Anticancer Treatments.
Schneider M.P., Achtari Jeanneret L., Chevaux B., Backes C., Wagner A.D., Bugnon O., Luthi F., Locatelli I., 2019. Frontiers in Pharmacology, 9 p. 1567. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C48EDB2AC56]
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
Smyth E., Knödler M., Giraut A., Mauer M., Nilsson M., Van Grieken N., Wagner A.D., Moehler M., Lordick F., 2019. Frontiers in oncology, 9 p. 1320. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3144C154E1E3]
2018
 
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.
Özdemir B.C., Csajka C., Dotto G.P., Wagner A.D., 2018/09/10. Journal of clinical oncology, 36 (26) pp. 2680-2683. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1AE7BE4F2A08]
 
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
Cristina V., Mahachie J., Mauer M., Buclin T., Van Cutsem E., Roth A., Wagner A.D., 2018/07/01. JAMA oncology, 4 (7) pp. 1003-1006. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13A355872A91]
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E8B0234B5672]
 
Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn.
Özdemir B.C., Coukos G., Wagner A.D., 2018/04/01. Annals of oncology, 29 (4) p. 1067. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_888420F74085]
2017
 
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG.
Kataoka K., Kinoshita T., Moehler M., Mauer M., Shitara K., Wagner A.D., Schrauwen S., Yoshikawa T., Roviello F., Tokunaga M. et al., 2017/09. Gastric cancer, 20 (5) pp. 904-912. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_989189C4915D]
Chemotherapy for advanced gastric cancer.
Wagner A.D., Syn N.L., Moehler M., Grothe W., Yong W.P., Tai B.C., Ho J., Unverzagt S., 2017/08/29. The Cochrane database of systematic reviews, 8 pp. CD004064. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8819477F408B]
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
McNamara M.G., Bridgewater J., Lopes A., Wasan H., Malka D., Jensen L.H., Okusaka T., Knox J.J., Wagner D., Cunningham D. et al., 2017/04/12. BMC cancer, 17 (1) p. 262. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C96188F64686]
2016
 
Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy.
De Bari B., Porta L., Mazzola R., Alongi F., Wagner A.D., Schäfer M., Bourhis J., Ozsahin M., 2016/07. Critical reviews in oncology/hematology, 103 pp. 49-61. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EE057E94F72E]
Traitement curatif du cancer de l'oesophage: consensus multidisciplinaire multicentrique [Curative treatment for esophageal cancer: results of a multidisciplinary consensus]
Allemann P., Mantziari S., Wagner D., Digklia A., Ozsahin E., De Bari B., Dorta G., Godat S., Montserrat F., Sempoux C. et al., 2016/06/15. Revue medicale suisse, 12 (523) pp. 1165-1169. Peer-reviewed.
[URN][Pmid][serval:BIB_58E6531A0AFA]
 
Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
De Bari B., Jumeau R., Bouchaab H., Vallet V., Matzinger O., Troussier I., Mirimanoff R.O., Wagner A.D., Hanhloser D., Bourhis J. et al., 2016/06. Acta oncologica (Stockholm, Sweden), 55 (6) pp. 767-773. Peer-reviewed.
[DOI][Pmid][serval:BIB_BBF294B0BDC2]
 
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Koeberle D., Dufour J.F., Demeter G., Li Q., Ribi K., Samaras P., Saletti P., Roth A.D., Horber D., Buehlmann M. et al., 2016/05. Annals of oncology, 27 (5) pp. 856-861. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22900D1DA607]
Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT.
Cerny M., Dunet V., Prior J.O., Hahnloser D., Wagner A.D., Meuli R.A., Schmidt S., 2016/04. Clinical nuclear medicine, 41 (4) pp. 289-295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D1C7BBCC2191]
Advanced gastric cancer: Current treatment landscape and future perspectives.
Digklia A., Wagner A.D., 2016. World Journal of Gastroenterology, 22 (8) pp. 2403-2414. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9CE953713724]
 
Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma?
De Bari B., Ozsahin M., Bize P., Boussaha T., Deplanque G., Wagner D., Bourhis J., Denys A., 2016. Journal of Clinical Oncology, 34 (23) pp. 2798-2799. Peer-reviewed.
[DOI][Pmid][serval:BIB_3348C7FA293C]
 
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M., Delic M., Goepfert K., Aust D., Grabsch H.I., Halama N., Heinrich B., Julie C., Lordick F., Lutz M.P. et al., 2016. European Journal of Cancer, 59 pp. 160-170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8719495746AA]
 
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Bridgewater J., Lopes A., Wasan H., Malka D., Jensen L., Okusaka T., Knox J., Wagner D., Cunningham D., Shannon J. et al., 2016. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 27 (1) pp. 134-140. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B970CA4821B1]
2015
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).
Feilchenfeldt J., Varga Z., Siano M., Grabsch H.I., Held U., Schuknecht B., Trip A., Hamaguchi T., Gut P., Balague O. et al., 2015. British Journal of Cancer, 113 (5) pp. 716-721. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_917B8A7CB530]
Correction: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).
Feilchenfeldt J., Varga Z., Siano M., Grabsch H.I., Held U., Schuknecht B., Trip A., Hamaguchi T., Gut P., Balague O. et al., 2015. British Journal of Cancer, 113 (12) p. 1747. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E022C267229]
 
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
Moehler M., Baltin C.T., Ebert M., Fischbach W., Gockel I., Grenacher L., Hölscher A.H., Lordick F., Malfertheiner P., Messmann H. et al., 2015. Gastric Cancer, 18 (3) pp. 550-563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DB5317626E36]
 
Nouveautés et perspectives dans la prise en charge des cancers colorectaux et gastriques avancés [News and perspectives in the treatment of advanced gastric and colorectal cancers].
Diciolla A., Cristina V., De Micheli R., Digklia A., Wagner A.D., 2015. Revue Médicale Suisse, 11 (475) pp. 1122, 1124-1122, 1126. Peer-reviewed.
[Pmid][serval:BIB_6313089CA2F4]
2014
 
Traitement des tumeurs maligne du foie par radiologie interventionnelle: techniques intra-artérielles [Interventional radiology procedures for malignancies of the liver treatment: Intraarterial procedures].
Cristina V., Pracht M., Lachenal Y., Adib S., Boubaker A., Prior J., Denys A., Wagner A.D., Bize P., 2014/05. Revue Médicale Suisse, 10 (431) pp. 1130-2, 1134-5. Peer-reviewed.
[Pmid][serval:BIB_BDFA56A665FC]
 
Traitement des tumeurs malignes du foie par radiologie interventionnelle: techniques ablatives [Interventional radiology procedures for malignancies of the liver: ablation procedures].
Cristina V., Pracht M., Lachenal Y., Denys A., Wagner A.D., Bize P., 2014. Revue Médicale Suisse, 10 (431) pp. 1123-1126.
[Pmid][serval:BIB_55B7A1C15E3B]
2013
 
IS4-5 * IS TRIPLET SUPERIOR TO DOUBLET CHEMOTHERAPY IN ADVANCED GASTRIC CANCER?
Wagner A. D., 2013. pp. ix15-ix16 dans Annals of Oncology.
[DOI][WoS][serval:BIB_79D5FCE0BE74]
2012
 
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner A.D., Thomssen C., Haerting J., Unverzagt S., 2012. Cochrane Database of Systematic Reviews, 7 pp. CD008941. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_323AA9BE4D26]
2011
 
Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy.
Moehler M., Schwarz S., Wagner A.D., 2011. Current Cancer Drug Targets, 11 (6) pp. 681-687. Peer-reviewed.
[WoS][Pmid][serval:BIB_14FA9D22AE4C]
 
S3-Leitlinie "Magenkarzinom" - Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032-009-OL) [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].
Moehler M., Al-Batran S.E., Andus T., Anthuber M., Arends J., Arnold D., Aust D., Baier P., Baretton G., Bernhardt J. et al., 2011. Zeitschrift für Gastroenterologie, 49 (4) pp. 461-531. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4821781C47D8]
2010
 
Chemotherapy for advanced gastric cancer.
Wagner A.D., Unverzagt S., Grothe W., Kleber G., Grothey A., Haerting J., Fleig W.E., 2010. Cochrane Database of Systematic Reviews, 3 (3) pp. CD004064. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_408945228D7E]
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.
Dollinger M.M., Lautenschlaeger C., Lesske J., Tannapfel A., Wagner A.D., Schoppmeyer K., Nehls O., Welker M.W., Wiest R., Fleig W.E. et al., 2010. Bmc Cancer, 10 p. 457. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B8BD021BE3A3]
 
Traitements antiangiogéniques des cancers métastatiques du côlon et du rectum, du sein et du poumon: bénéfices et risques [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
Wagner A.D., Zaman K., Peters S., Montemurro M., Leyvraz S., 2010. Revue Médicale Suisse, 6 (250) pp. 1070-1073. Peer-reviewed.
[Pmid][serval:BIB_BA7767808A25]
2009
 
Advances in the pharmacological treatment of gastro-oesophageal cancer.
Wagner A.D., Wedding U., 2009. Drugs & Aging, 26 (8) pp. 627-646. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DBDE325D9745]
 
Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner A.D., Arnold D., Grothey A.A., Haerting J., Unverzagt S., 2009. Cochrane Database of Systematic Reviews 3 pp. CD005392. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2799902E0FBD]
 
Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner A.D., Moehler M., 2009. Current Opinion in Oncology, 21 (4) pp. 381-385. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8B9FB9947BCD]
 
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Wagner A.D., Buechner-Steudel P., Moehler M., Schmalenberg H., Behrens R., Fahlke J., Wein A., Behl S., Kuss O., Kleber G. et al., 2009. British journal of Cancer, 101 (11) pp. 1846-1852. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2F8F17504A85]
2008
Moeglichkeiten der systemischen Therapie im metastasierten Stadium [Treatment options for chemotherapy in metastatic gastric cancer]
Wagner D., Stah M, 2008/03. Onkologe, 14 (4) pp. 381-388. Peer-reviewed.
[URN][DOI][WoS][serval:BIB_E2214C781396]
2007
 
Docetaxel for advanced gastric cancer?
Wagner A.D., Wedding U., Kuss O., Höffken K., 2007. Journal of Clinical Oncology, 25 (17) pp. 2490-1; author reply 2491-3. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD69CACB4265]
 
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Wagner A.D., Buechner-Steudel P., Wein A., Schmalenberg H., Lindig U., Moehler M., Behrens R., Kleber G., Kuss O., Fleig W.E., 2007. Annals of Oncology, 18 (1) pp. 82-87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0988E08A59FB]
2006
 
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E., 2006. Journal of Clinical Oncology, 24 (18) pp. 2903-2909. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6E2B7F7578D3]
 
The role of chemotherapy in patients with established gastric cancer.
Wagner A.D., Schneider P.M., Fleig W.E., 2006. Best Practice and Research. Clinical Gastroenterology, 20 (4) pp. 789-799. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6D5F8B57D8F5]
2005
 
Chemotherapy for advanced gastric cancer.
Wagner A.D., Grothe W., Behl S., Kleber G., Grothey A., Haerting J., Fleig W.E., 2005. Cochrane Database of Systematic Reviews, 11 (2) pp. CD004064.
[DOI][Pmid][serval:BIB_858743322F30]
2001
Joint and muscle pain with mononeuritis multiplex, tetraparesis, and myocardial infarction in a previously healthy adult.
Wagner A.D., Feist T., Prondzinsky R., Fleig W.E., Keysser G., 2001. Annals of the Rheumatic Diseases, 60 (11) pp. 1003-1006. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1071CB06EA4C]
1998
 
19jähriger Patient mit generalisiertem Krampfanfall und rezidivierenden Thrombosen unter Heparintherapie [Heparin-induced thrombocytopenia type-II]
Wagner A.D., Kleber G., Lindner A., Pötzsch B., Fleig W.E., 1998. Der Internist, 39 (7) pp. 766-769. Peer-reviewed.
[DOI][WoS][serval:BIB_CA3FC7A4DB46]
1996
 
Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease.
Brauchle M., Madlener M., Wagner A.D., Angermeyer K., Lauer U., Hofschneider P.H., Gregor M., Werner S., 1996. American Journal of Pathology, 149 (2) pp. 521-529. Peer-reviewed.
[WoS][Pmid][serval:BIB_5385B6186984]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University